RE:RE:RE:RE:RE:RE:RE:Bayer looking for a "mid-size M&A transaction" in oncologyBayer sees "good value" in moving on M&A transactions of between US$5 Billion to US$10 Billion
And the list of Big Pharma companies looking to hit their M&A "sweet spot" of US$5 Billion to US$25 Billion is growing, particularly given the regulatory environment presented by the FTC rulings.
Note also that the FTC announced that it will be reviewing the merger of the PGA and LIV Golf with the intent of overturning the deal.
So Pfizer's US$43 Billion acquistion of Seagen will likely be overturned and Pfizer may very well be turning to acquiring ONCY for between US$10 and US$15 Billion which would not undergo FTC scrutiny.